{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:07:14Z","timestamp":1789452434738,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.110994","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:29:47Z","timestamp":1771417787000},"page":"110994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Betty","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Moningi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Tendulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Weight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-6230","authenticated-orcid":false,"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2026.110994_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.110994_bib0002","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.110994_bib0003","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.110994_bib0004","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.110994_bib0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/23523735241301646","article-title":"Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: evaluating treatment outcomes","volume":"10","author":"Rutten","year":"2024","journal-title":"Bladder Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.110994_bib0006","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/MOU.0000000000001034","article-title":"The role of surgery for locally advanced urothelial cancers","volume":"32","author":"Ibilibor","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.110994_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/BLC-170130","article-title":"Role of radical cystectomy in non-organ confined bladder cancer: a systematic review","volume":"4","author":"Li","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2026.110994_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.05.015","article-title":"Consolidative surgery for advanced urothelial carcinoma following induction Enfortumab Vedotin and\/or Immune checkpoint inhibitor therapy: a multicenter analysis","author":"Roberson","year":"2025","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.urolonc.2026.110994_bib0009","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.3390\/jcm13247498","article-title":"Is there a role for surgery in the treatment of metastatic urothelial carcinoma?","volume":"13","author":"Bhalla","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.110994_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urology.2008.07.035","article-title":"Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy","volume":"73","author":"Kassouf","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2026.110994_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-200101000-00015","article-title":"Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.110994_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf259","article-title":"Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure?","volume":"30","author":"Jang","year":"2025","journal-title":"Oncologist"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:39:16Z","timestamp":1776577156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000049"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.110994","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of local therapy following enfortumab vedotin in advanced urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.110994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110994"}}